Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445315 | 0.92 | L3MBTL1 (0.57) | HTR6L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL14595058 | 0.80 | L3MBTL1 (0.63) | HTR6L3MBTL1KDM4EUBE2NALOX5 | |
| SCHEMBL13302222 | 0.78 | ALOX5 (0.57) | HTR6L3MBTL1HTR2AHTR7MEN1 | |
| SCHEMBL3335935 | 0.76 | MAPT (0.48) | HTR6MEN1KMT2AKDM4EDRD2 | |
| SCHEMBL13302163 | 0.75 | HTR6 (0.52) | HTR6L3MBTL1HTR2AHTR7DRD2 | |
| SCHEMBL13302223 | 0.75 | HTR6 (0.55) | HTR6L3MBTL1HTR2AHTR7KDM4E | |
| SCHEMBL13302272 | 0.75 | HTR6 (0.62) | HTR6L3MBTL1HTR2AHTR7PPARG | |
| SCHEMBL14216562 | 0.74 | ALOX5 (0.53) | HTR6L3MBTL1HTR2AHTR7MEN1 | |
| SCHEMBL13302285 | 0.74 | L3MBTL1 (0.51) | HTR6L3MBTL1MEN1KMT2APPARG | |
| SCHEMBL10002621 | 0.74 | AGTR1 (0.51) | HTR6MEN1KMT2AKDM4EUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | HTR6 881/4885L3MBTL1 2503/4885HTR2A 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.